InMed Pharmaceuticals announced it received conditional approval from the TSX to list its common shares in the exchange.
As quoted in the press release:
Final approval of the listing on the TSX remains subject to InMed fulfilling certain customary listing conditions of the TSX on or before the TSX-imposed deadline of May 29, 2018. The Company expects that it will satisfy such conditions in advance of the TSX-imposed deadline. Upon listing on the TSX, the Common Shares will continue to trade under the symbol ‘IN’.
“Graduating to the TSX is a significant accomplishment for InMed,” said Eric A. Adams, CEO & President. “This milestone furthers our corporate goal of securing a leadership position in this high-growth sector. InMed is one of only a few pure-play cannabinoid biopharmaceutical companies to be trading on one of the world’s senior stock exchanges.”